Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)
STOCKHOLM, July 21, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer's Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021. The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.
The presentations regarding lecanemab include oral presentations about the preliminary assessment of the clinical effect of lecanemab following 18 months of treatment in the open-label extension of the Phase 2b proof of concept study (201 study) in subjects with early Alzheimer's disease and preliminary screening and baseline characteristics of the Phase 3 clinical study, AHEAD 3-45, for preclinical (asymptomatic) Alzheimer's disease.
Eisai oral presentations
Eisai poster presentations
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
For further information, please contact:
Oskar Bosson, Vice President Communications and Investor Relations, BioArctic AB
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Company Codes: Stockholm:BIOAB, ISIN:SE0010323311, RICS:BIOAB.ST, Bloomberg:BIOAB@SS, RICS:BIOAB.ST
© 2021 PR Newswire. All Rights Reserved.